The Future Prospects of Pharmaceutical Intermediates for the Explosive Growth of Generic Drugs

Author:

Pharmaceutical intermediates have received much attention and favor from all walks of life. The Chinese government also attaches great importance to the development of pharmaceutical intermediates and has issued a series of incentive policies and measures. Under the strong promotion of the government, the pharmaceutical intermediate industry in China has developed rapidly. Currently, it has basically met the requirements of chemical raw materials and intermediates for pharmaceutical production.
According to the "Market Research and Investment Analysis Report on the Chinese Pharmaceutical Intermediates Industry" released by the Prospective Industry Research Institute, it is expected that with the expiration of the drug, generic drugs will experience explosive growth with price advantages in the next five to ten years, and production and sales are expected to soar significantly. The outbreak of generic drugs will bring broader market space and good development opportunities to pharmaceutical intermediates, with a promising future.
Pharmaceutical intermediates refer to some chemical raw materials or products used in the pharmaceutical synthesis process, and are also an important component of fine chemicals. They have gradually become the core of the development of chemical industry in various countries. In recent years, China has made significant progress in fine chemicals, and the refining rate has been continuously increasing, creating a good atmosphere for the development of pharmaceutical intermediates.
Due to its high investment efficiency, high profit margin, and high added value, pharmaceutical intermediates have received much attention and favor from all walks of life. The Chinese government also attaches great importance to the development of pharmaceutical intermediates and has issued a series of incentive policies and measures.
Under the strong promotion of the government, the pharmaceutical intermediate industry in China has developed rapidly. Currently, it has basically met the requirements of chemical raw materials and intermediates for pharmaceutical production, and presents the following six characteristics.
Firstly, pharmaceutical intermediate enterprises are mostly private enterprises, with a generally small investment scale, with an investment amount of between millions and 120 million. However, their operations are relatively flexible and they can quickly and effectively respond to market changes;
Secondly, the distribution of pharmaceutical intermediate enterprises is relatively concentrated, mainly in Jiangsu and Zhejiang, especially in Taizhou, Zhejiang, and Jintan, Jiangsu, where a large number of pharmaceutical intermediate enterprises are gathered;
Thirdly, pharmaceutical intermediate enterprises are facing increasing environmental pressure, and it is imperative to build environmental protection treatment facilities;
Fourth, the rapid iteration of product updates and the endless emergence of new varieties force pharmaceutical intermediate companies to follow up or improve their processes;
Fifth, the competition in the pharmaceutical intermediate industry is fierce and disorderly, and more and more small and medium-sized chemical enterprises are joining it, which is not conducive to the clustered development of the pharmaceutical intermediate industry;
Sixth, pharmaceutical intermediate companies generally lack innovation, have low-level duplication, and have independent intellectual property rights in intermediate drugs worldwide.
Judging from the above development characteristics, China's pharmaceutical intermediates still lag far behind the international advanced level. In the future, when promoting the development of the pharmaceutical intermediate industry, it is necessary to attach importance to scientific research investment, establish engineering centers based on interdisciplinary, multi-directional, and high starting point standards, provide a platform for the birth of new products, and carry out prediction and evaluation work to achieve the rapid and healthy development of pharmaceutical intermediates.
In general, as Chinese pharmaceutical companies develop generic drugs, pharmaceutical intermediates are expected to benefit from this. However, before that, problems such as overcapacity and vicious competition need to be addressed.

Related News

2023 Company Safety Month Event Press Release

2023-06-02

On the morning of June 2, 2023, at 8:40 am, the launch ceremony of the safety production month activity with the theme of "Everyone talks about safety, everyone knows emergency" was officially held in the lobby of the company's first floor. The launch ceremony was presided over by Zou Rui, the person in charge of the company's safety and environmental protection department, and all department heads and company employees attended the meeting.

Hubei Guangchen Pharmaceutical Allopurinol API Transfer A

2023-01-12

On January 12, 2023, our company transferred allopurinol API to A, and the packaging specifications of this product are: 1kg/barrel, 5kg/barrel, 10kg/barrel, 25kg/barrel, or can be provided according to customer requirements.

Hubei Guangchen Pharmaceutical: Gather in Yan'an to Start a Red Culture Journey

2022-07-08

In order to inherit and carry forward the Yan'an spirit of self-reliance and hard struggle, and further enhance the cohesion and combat effectiveness of grassroots party organizations, from June 27-29, all party members and management of the Party branch of Hubei Guangchen Pharmaceutical Industry jointly went to Yan'an to carry out a red culture tour, pursue the footprints of revolutionary martyrs, inherit the red gene, and draw on the strength of progress.

Hubei Guangchen Pharmaceutical Phase II R&D Building Project Successfully Capped

2022-04-19